Foghorn Therapeutics

Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression.

[Foghorn Therapeutics @foghorntx]

Read our Q2 2026 update, highlighting continued progress across our pipeline, including advancement of FHD-909 (LY4050784) with Lilly and a new oral small molecule program in immunology and inflammation that expands our platform beyond oncology: https://t.co/olslSbDzHA $FHTX

[Foghorn Therapeutics @foghorntx]

Join us for @GoldmanSachs Global Healthcare Conference, where $FHTX will discuss progress across our first-in-class portfolio of novel therapies designed to address cancers with significant unmet need. Learn more: https://t.co/KRqJO97oFQ

[Foghorn Therapeutics @foghorntx]

This month, we’ll participate in three investor conferences to discuss progress across our first-in-class oncology pipeline. See the conferences and learn more: https://t.co/HbE1VoFdnl $FHTX

[Foghorn Therapeutics @foghorntx]

Today, we shared our Q1 2026 financial and corporate update.

Read the full announcement for the latest on our pipeline progress and financial results: https://t.co/Q84YrqzKqW

$FHTX

[Foghorn Therapeutics @foghorntx]

At the 2026 @AACR Annual Meeting, we presented new preclinical data for our selective SMARCA2 inhibitor, FHD-909, and for Selective CBP, EP300, and ARID1B degrader programs. See the findings: https://t.co/eyKPNmKe2C

#AACR26

[Foghorn Therapeutics @foghorntx]

$FHTX will present new preclinical data at #AACR2026 across our pipeline, highlighting differentiated profiles of our programs and their potential in difficult-to-treat cancers. Read here: https://t.co/jQeJNigoks #AACR26

[Foghorn Therapeutics @foghorntx]

2026 is an important year for Foghorn. Today, we provided a financial update for 2025 and corporate outlook for the year ahead. Read the announcement to see recent highlights and milestones for the year ahead: https://t.co/ygnlH7IJhA $FHTX

[Foghorn Therapeutics @foghorntx]

$FHTX will be at two investor conferences in March to discuss our first-in-class pipeline targeting the chromatin regulatory system. Learn more: https://t.co/9wYaCvwPGV

[Foghorn Therapeutics @foghorntx]

Join us in welcoming Ryan Maynard as CFO of $FHTX. Read about his expertise driving financial strategy, capital markets execution, and operational performance, and how that helps accelerate our mission: https://t.co/G6ykIfx0BN

[Foghorn Therapeutics @foghorntx]

As we advance our first-in-class pipeline focused on cancers with significant unmet need, hear from $FHTX CEO Adrian Gottschalk at the Guggenheim Emerging Outlook: Biotech Summit. Register here: https://t.co/5HuPUkmv7B

[Foghorn Therapeutics @foghorntx]

Today, we announced a $50M equity financing, with a look ahead to our 2026 priorities and progress across the $FHTX first-in-class oncology pipeline: https://t.co/t9VV84Za3q #JPM2026

[Foghorn Therapeutics @foghorntx]

We’re heading to the Evercore Healthcare Conference next week. CEO Adrian Gottschalk will join a fireside chat on 12/4 at 9:10am ET to share insights on our platform and pipeline. https://t.co/C2fZBRUr4R
$FHTX

[Foghorn Therapeutics @foghorntx]

Our Q3 2025 update highlights continued progress across our pipeline and leadership in targeted protein degradation and chromatin regulation. Read more: https://t.co/0rJwRO7ACx $FHTX

[Foghorn Therapeutics @foghorntx]

$FHTX will participate in three upcoming investor conferences to share progress across our pipeline and how our science in chromatin regulation and targeted protein degradation is redefining what’s possible in oncology. Learn more: https://t.co/f3f6airb44

[Foghorn Therapeutics @foghorntx]

Today we’re sharing progress across our selective protein degrader portfolio — including programs targeting ARID1B, CBP and EP300. Join us at 12:00 p.m. ET to learn more: https://t.co/jFW0rfZ31J $FHTX

[Foghorn Therapeutics @foghorntx]

Reminder: Register to join our investor event for updates on our Selective ARID1B, Selective CBP & Selective EP300 degrader programs.

Register: https://t.co/zZgV3ToFcp

[Foghorn Therapeutics @foghorntx]

$FHTX is presenting new progress from our selective ARID1B degrader program at the 8th Annual TPD Summit. Learn more and join our Oct. 30 event for updates across our Selective ARID1B, Selective CBP, and Selective EP300 degrader programs: https://t.co/WwrsQzhalu

[Foghorn Therapeutics @foghorntx]

$FHTX will take part in several investor conferences this September to share updates on our platform and pipeline. Details: https://t.co/z58ZZ7qYLT

[Foghorn Therapeutics @foghorntx]

We shared our Q2 2025 financial and corporate update today. With continued pipeline progress and a strong balance sheet, we’re well positioned to advance our mission of delivering innovative cancer therapies.

Read the full update: https://t.co/dRqERfMcrN $FHTX

[Foghorn Therapeutics @foghorntx]

Our CSO Steven Bellon shares key insights from Foghorn’s 2nd Chromatin Regulation Summit, where leaders in #ProteinDegradation & #InducedProximity discussed the future of drug discovery. Read here: https://t.co/99vpved8Fr